139 related articles for article (PubMed ID: 16085563)
1. Troglitazone overcomes doxorubicin-resistance in resistant K562 leukemia cells.
Davies GF; Roesler WJ; Juurlink BH; Harkness TA
Leuk Lymphoma; 2005 Aug; 46(8):1199-206. PubMed ID: 16085563
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Yousefi B; Samadi N; Baradaran B; Rameshknia V; Shafiei-Irannejad V; Majidinia M; Targhaze N; Zarghami N
Cell Mol Biol (Noisy-le-grand); 2015 Dec; 61(8):118-22. PubMed ID: 26718439
[TBL] [Abstract][Full Text] [Related]
3. Troglitazone inhibits histone deacetylase activity in breast cancer cells.
Davies GF; Ross AR; Arnason TG; Juurlink BH; Harkness TA
Cancer Lett; 2010 Feb; 288(2):236-50. PubMed ID: 19699029
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of tensin homolog deleted on chromosome ten (PTEN) by ciglitazone sensitizes doxorubicin-resistance leukemia cancer cells to treatment.
Mashayekhi S; Yousefi B; Tohidi E; Darband SG; Mirza-Aghazadeh-Attari M; Sadighparvar S; Kaviani M; Shafiei-Irannejad V; Kafil HS; Karimian A; Jadidi-Niaragh F; Majidinia M
J Cell Biochem; 2019 Sep; 120(9):15719-15729. PubMed ID: 31087712
[TBL] [Abstract][Full Text] [Related]
5. Troglitazone reverses the multiple drug resistance phenotype in cancer cells.
Davies GF; Juurlink BH; Harkness TA
Drug Des Devel Ther; 2009 Sep; 3():79-88. PubMed ID: 19920924
[TBL] [Abstract][Full Text] [Related]
6. Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells.
Misra R; Sahoo SK
Mol Pharm; 2011 Jun; 8(3):852-66. PubMed ID: 21480667
[TBL] [Abstract][Full Text] [Related]
7. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Xu HB; Li L; Liu GQ
Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial amplification selectively increases doxorubicin sensitivity in breast cancer cells with acquired antiestrogen resistance.
Skildum A; Dornfeld K; Wallace K
Breast Cancer Res Treat; 2011 Oct; 129(3):785-97. PubMed ID: 21128112
[TBL] [Abstract][Full Text] [Related]
9. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
Gao M; Xu Y; Qiu L
J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
[TBL] [Abstract][Full Text] [Related]
10. Gallic acid enhances pirarubicin‑induced anticancer in living K562 and K562/Dox leukemia cancer cells through cellular energetic state impairment and P‑glycoprotein inhibition.
Aye KT; Wattanapongpitak S; Supawat B; Kothan S; Udomtanakunchai C; Tima S; Pan J; Tungjai M
Oncol Rep; 2021 Oct; 46(4):. PubMed ID: 34476509
[TBL] [Abstract][Full Text] [Related]
11. Syntheses and biological activities of 3'-azido disaccharide analogues of daunorubicin against drug-resistant leukemia.
Zhang G; Fang L; Zhu L; Zhong Y; Wang PG; Sun D
J Med Chem; 2006 Mar; 49(5):1792-9. PubMed ID: 16509594
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin-transferrin conjugate selectively overcomes multidrug resistance in leukaemia cells.
Łubgan D; Jóźwiak Z; Grabenbauer GG; Distel LV
Cell Mol Biol Lett; 2009; 14(1):113-27. PubMed ID: 18850074
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanism study of chemosensitization of doxorubicin-resistant human myelogenous leukemia cells induced by a composite polymer micelle.
Han M; Diao YY; Jiang HL; Ying XY; Chen DW; Liang WQ; Gao JQ
Int J Pharm; 2011 Nov; 420(2):404-11. PubMed ID: 21945184
[TBL] [Abstract][Full Text] [Related]
14. [Down-Regulation of MiR-125b Reverses Drug Resistance of Doxorubicin-Resistant Leukemia Cells].
Deng YM; Luo AL; Li GF; Cai MS; Xu L; Yan MX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1610-1615. PubMed ID: 30501692
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of p38 MAPK diminishes doxorubicin-induced drug resistance associated with P-glycoprotein in human leukemia K562 cells.
Chen Y; Zhao Y; Wang C; Xiao X; Zhou X; Xu G
Med Sci Monit; 2012 Oct; 18(10):BR383-8. PubMed ID: 23018344
[TBL] [Abstract][Full Text] [Related]
16. Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin.
Xue C; Wang C; Liu Q; Meng Q; Sun H; Huo X; Ma X; Liu Z; Ma X; Peng J; Liu K
Tumour Biol; 2016 Jul; 37(7):8587-97. PubMed ID: 26733176
[TBL] [Abstract][Full Text] [Related]
17. Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPARγ-dependent manner in leukemia cells.
Yousefi B; Azimi A; Majidinia M; Shafiei-Irannejad V; Badalzadeh R; Baradaran B; Zarghami N; Samadi N
Tumour Biol; 2017 Oct; 39(10):1010428317716501. PubMed ID: 28978268
[TBL] [Abstract][Full Text] [Related]
18. Icariin enhances cytotoxicity of doxorubicin in human multidrug-resistant osteosarcoma cells by inhibition of ABCB1 and down-regulation of the PI3K/Akt pathway.
Wang Z; Yang L; Xia Y; Guo C; Kong L
Biol Pharm Bull; 2015; 38(2):277-84. PubMed ID: 25747987
[TBL] [Abstract][Full Text] [Related]
19. Stimulating basal mitochondrial respiration decreases doxorubicin apoptotic signaling in H9c2 cardiomyoblasts.
Deus CM; Zehowski C; Nordgren K; Wallace KB; Skildum A; Oliveira PJ
Toxicology; 2015 Aug; 334():1-11. PubMed ID: 25997894
[TBL] [Abstract][Full Text] [Related]
20. Does P-glycoprotein play a pivotal role in the drug resistance of an MDR variant, K562/Dox?
Hu X; Yang H; Pan QR; Zheng S
Chemotherapy; 1995; 41(4):296-305. PubMed ID: 7555211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]